Editas Medicine Stock (NASDAQ: EDIT) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 110.000 / 1.891M |
Day Range | - - - |
52 Wk Range | 5.511 - 11.910 |
Market Cap | $461.337M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 24 |
Short Interest | 25.23% |
Days to Cover | 9.23 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Editas Medicine (NASDAQ: EDIT) through any online brokerage.
Other companies in Editas Medicine’s space includes: Skye Bioscience (NASDAQ:SKYE), KalVista Pharma (NASDAQ:KALV), Humacyte (NASDAQ:HUMA), Celcuity (NASDAQ:CELC) and Voyager Therapeutics (NASDAQ:VYGR).
The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Citigroup on Thursday, February 29, 2024. The analyst firm set a price target for 16.00 expecting EDIT to rise to within 12 months (a possible 185.20% upside). 18 analyst firms have reported ratings in the last year.
The stock price for Editas Medicine (NASDAQ: EDIT) is $5.61 last updated April 18, 2024 at 7:42 PM EDT.
There are no upcoming dividends for Editas Medicine.
Editas Medicine’s Q1 earnings are confirmed for Friday, May 3, 2024.
There is no upcoming split for Editas Medicine.
Editas Medicine is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.